Pharma Award

The awards for Innovation and Sustainability “The Golden Tablet” and “Most Innovative Product” have been granted to pharmaceutical companies since 2000. The recipients of the “Golden Tablet” award, also known as the Pharma Accolade, are chosen on the basis of Pharma Trend survey, which identifies the most innovative and sustainable pharmaceutical companies within a field of study. For this survey, which is conducted on behalf of the trade journal Pharma Barometer, doctors with various specializations, pharmacists and patients complete an online questionnaire about sustainability and innovation in the pharmaceutical industry.

Pharma Trend – Image & Innovation Award 2022

On September 13, the winners of the “Golden Tablet” and “Most Innovative Product“ awards were revealed at the “Pharma Trend – Image & Innovation” awards ceremony. Additionally, the Pharma Trend ranking of the best pharmaceutical companies was published for the seventh time.

The Eurecon Verlag event is under the patronage of the Bavarian State Ministry of Health and Care. The keynote speech gave the patron, Bavarian Health Minister Klaus Holetschek. The festive award ceremony was moderated by TV presenter Tamara Sedmak (Sat 1, n-tv, N24).

Partners of the Pharma Trend Image & Innovation Award are Ashfield, Harris Interactive and BioM; sponsors are Bundesverband Mergers & Acquisitions, Business Wire, Dorothea Küsters Life Science Communications, GESDAT, JJ Sustainability, Lucky7even, MCC and tiny web. Media partners of the award ceremony are Apovid, Biermann Medizin, esanum, Healthcare Marketing, Vidal MMI (Gelbe Liste) and PharmaBarometer, the magazine for innovation and sustainability.

Pharma Award: Golden Tablet

The Golden Tablet Award for the best pharmaceutical companyThe decisive factors in choosing a winner for “The Golden Tablet” Pharma award are the quality of information about the sales force, education events, information on the product and pricing, as well as the companies’ research activities and innovative strength, value for money, and the quality of the products. It appears that doctors place a lot of value on the R&D efforts of the Golden Tablet winners, as well as on transparent information about the companies. Doctors also value the companies’ resistance to corruption highly. In terms of the medications themselves, the most important considerations were the products’ effectiveness and tolerability, and the benefits in treatment observed to date.

“The Golden Tablet” 2022 Award Recipients

The basis for the ranking and the awards is the Pharma Trend benchmark study, which has been conducted annually among physicians in Germany since 2000 in the Rx category and since 2018 also in the OTC and Orphan Drugs categories, and since 2019 additionally in the Specialty Care category on behalf of the PharmaBarometer magazine. In 2021, the study was expanded to include the categories “Diagnostics” and “Digital Health Applications”. With the expansion of Pharma Trend, companies in pharmaceuticals and medical technology are assessed on innovation and sustainability via their key stakeholders – physicians, pharmacists and patients. This year, Pharma Trend was conducted online with 700 physicians, including allergists, general practitioners, dermatologists, gynecologists, oncologists/hematologists, pediatricians and urologists, as well as 100 pharmacists and 600 patients.

This year, the following companies were honored with the “Golden Tablet” award:

“The Golden Tablet” Award Winners since 2000:

YearGeneral Practice & Internal MedicineNeurologyUrologyDermatologyENT medicineGynecologyPediatricsPneumologyOrthopedics and RheumatologyDiabetologyCardiologyOphthalmologyOncologyGastroenterologistsPharmacistsPatients
2022BioNTechJanssen-CilagJenapharmInfectoPharmBionorica
2021BioNTechJanssen-CilagBioNTechBioNTechBioNTech
2020Janssen-CilagJenapharmInfectoPharm
2019JenapharmInfectoPharmRoche
2018JenapharmInfectoPharmLillyRatiopharm
2017BiogenAstellasJenapharmInfectoPharmLillyRoche
2016Janssen-CilagAstellasInfectoPharmJenapharmInfectoPharmBoehringer IngelheimRoche
2015BiogenAstellasJenapharmInfectoPharmBayerRoche
2014Berlin-ChemieBiogenAstellasGaldermaJenapharmInfectoPharmNovo NordiskRoche
2013BayerJanssen-CilagGaldermaJenapharmInfectoPharmNovartisBayer
2012Berlin-ChemieNovartisAstellasBasileaJenapharmInfectoPharmBerlin-Chemie
Bayer
Boehringer IngelheimAlconRoche
2011NovartisNovartisBayerBasileaJenapharmInfectoPharmAmgenBerlin-ChemieAlconRoche
2010NovartisJanssen-CilagAstellasBasileaJenapharmInfectoPharmNovartisMSDAlconRoche
2009NovartisJanssen-CilagAstellasBasileaJenapharmInfectoPharmMSDNovartisAlconRoche
2008NovartisJanssen-CilagAlmirall HermalHexalJenapharmInfectoPharmMSDMSDAlconRoche
2007MSDJanssen-CilagAstellasHexalJenapharmInfectoPharmMSDSanofi - AventisPfizerRoche
2006AstraZenecaJanssen-CilagAstellasNovartisJenapharmInfectoPharmBoehringer IngelheimMSDSanofi - AventisAlcon
2005PfizerEli LillyBayerNovartisJenapharmInfectoPharmBoehringer IngelheimMSDNovo NordiskRoche
2004PfizerPfizerTakedaHermalJenapharmInfectoPharmBoehringer IngelheimMSDNovo NordiskAventis
2003PfizerPfizerTakedaHermalJenapharmInfectoPharmGlaxoSmithKlineMSD
2002MSDJanssen-CilagTakedaEssex PharmaScheringInfectoPharm
2001MSDJanssen-CilagTakedaAventisAventisSchering
2000MSDNovartisTakedaHermalAventis
YearGeneral Practice & Internal MedicineNeurologyUrologyDermatologyENT medicineGynecologyPediatricsPneumologyOrthopedics and RheumatologyDiabetologyCardiologyOphthalmologyOncologyGastroenterologistsPharmacistsPatients

Pharma Award: Most innovative Product

Award for most innovative produkt in the medical sectorThe effectiveness and tolerability of the products, and the benefits in treatment observed so far are the most decisive criteria in granting for the “Most Innovative Product” award.

Early benefit assessment of medications

The medications suggested by the doctors as the most innovative product were generally introduced in the 36 months prior to the spring release of the annual survey or had received an extension that was significant to the treatment development process. The Pharma Trend results are therefore highly valuable in the early assessment of the benefits of the medications from the users’ perspective in comparison to earlier treatments.

“Most Innovative Product” 2022 Award Recipients

What differentiates the “Most Innovative Product“ award from other accolades in the pharmaceutical industry is its jury: the benefits of the medication are evaluated exclusively by doctors, pharmacist and patients, based on their experience of applying the treatments.

The winners of the awards 2022 are:

  • Algovir by Hermes Arzneimittel (pharmacists, patients)
  • Cariban by ITF Pharma (gynecologists)
  • CDR132L by Cardior Pharmaceuticals (leap innovations)
  • Comirnaty by BioNTech (general practitioners, pediatricians)
  • DeflaGyn by Exeltis (gynecologists)
  • dermanostic by Dermanostic (dermatologists)
  • Dulcosoft by Sanofi (pharmacists)
  • Enhertu by Daiichi Sankyo (oncologists/hematologists)
  • Klisyri by Almirall (dermatologists)
  • MyIUS by Jenapharm (gynecologists)
  • Nubeqa by Bayer Vital (urologists)
  • Oyono by Divapharma (pharmacists)
  • Palforzia by Aimmune (allergists)
  • Paxlovid by Pfizer (general practitioners)
  • Ryeqo by Gedeon Richter (gynecologists)
  • Slinda by Exeltis (gynecologists)
  • Voxzogo by BioMarin (pediatricians)

“Most Innovative Product” Winners since 2000:

YearGeneral Practice & Internal MedicineNeurologyUrologyDermatologyENT medicineGynecologyPediatricsPneumologyOrthopedics and RheumatologyDiabetologyCardiologyOphthalmologyOncologyGastroenterologyPain therapistsOrphan DrugsSpecialty carePharmacistsPatientsDigital health appsDiagnosticsLeap Innovations
2022Comirnaty
Paxlovid
NubeqaKlisyriPalforziaCariban
DeflaGyn
Ryeqo
Slinda
ComirnatyVoxzogoEnhertuAlgovir
Dulcosoft
Oyono
AlgovirMyIUSdermanosticCDR132L (Cardior Pharmaceuticals)
RCS-21 (RNATICS)
PAN004 (Pantherna Therapeutics)
2021ComirnatyErleadaTolakSlinda
DeflaGyn
Hepcludex
Poteligeo
Pemazyre
ImmunoBONMindable App (General Practice)
Mika App (Urology)
MyIUS (Gynecology)
SARS-CoV-2 Antigen Test (Roche Diagnostics)
AVENIO NGS (Roche Diagnostics)
FYB 207 Formycon
ETH 47 Ethris
PRS - 220 Pieris
2020ErleadaKyleenaSlenytoStelaraMoventigTAKHZYROspermidineLIFE
Thomapyrin Tension Duo
2019KyleenaSlenytoStelara
Xeljanz
Lynparza
TAKHZYRO
Canesten Extra
Femannose
BOCAhealth
2018OcrevusTremfyaKyleenaScabioralJardianceJorvezaBlincyto
Hemlibra
Radionuklide und Radiopharmaka
2017Ocrevus
Zinbryta
KyleenaJardianceStelara
2016BrintellixXtandiAcarizaxJardianceOpdivo
2015ForxigaTecfidera Lemtrada BrintellixXtandiEsmyaBexseroTrulicityImbruvica
2014ForxigaTecfideraBetmigaMirvasoJaydessBexseroTresibaEyleaKadcyla
2013XareltoZytigaPicatoEsmyaBexseroSeebriEylea
2012XareltoGilenyaZytigaToctinoZoelyInfectodexa KruppBydureonXareltoLucentisAfinitor Zelboraf
2011DaxasGilenyaLevitraToctinoQlairaInfectodexa KruppProliaVictozaLucentisTasigna
2010PradaxaValdoxanPriligy DuodartToctinoQlairaPrevenar 13OnbrezProliaLucentisNplate Iressa
2009RasilezValdoxanPriligyToctinoQlairaSynflorixAclastaJanuviaLucentisAvastin
2008JanuviaInvegaRaptivaGrazaxGardasilGardasilAclastaJanuviaLucentisAvastin
2007ExforgeAbilifyYentreveGrazaxGardasilGardasilBonvivaByettaLucentisSutent
2006InegyAbilifyYentreveRaptivaYentreveSingulairXolairBonvivaExuberaCombigan
2005InegyAbilifyYentreveRaptivaYentreveSingulairAlvescoForsteoLevemirAvastin
2004EzetrolCipralexCialisElidelNuvaRingElidelSpirivaBextraLantusErbitux
2003EzetrolZeldoxCialisProtopicNuvaRingElidelSpirivaFosamax
2002VioxxZyprexaViagraProtopicLafammeSingulair
2001VioxxZyprexaViagraAeriusAeriusYasmin
2000VioxxZyprexaViagraPropeciaNasonex
YearGeneral Practice & Internal MedicineNeurologyUrologyDermatologyENT medicineGynecologyPediatricsPneumologyOrthopedics and RheumatologyDiabetologyCardiologyOphthalmologyOncologyGastroenterologyPain therapistsOrphan DrugsSpecialty carePharmacistsPatientsDigital health appsDiagnosticsStartups

Pharma Barometer “Honorary Award”

As the organizer of the Pharma Trend Image & Innovation Award, Eurecon Verlag has initiated the “Pharma Barometer Ehrenpreis”. This award promotes charitable, sustainable engagement. Since 2005, more than 240,000.00 Euro have supported the work of various organizations, including the following projects, patient groups, organizations and organisators:

  • 2019: Anja Gehlken, first chairman of the SCHAKI e.V.
  • 2018: Prof. Dr. Wolfgang M. Heckl, General Director German Museum
  • 2012: Deutsche Blinden- und Sehbehindertenverband e.V. (DBSV)
  • 2011: Deutsche Herzstiftung e.V.
  • 2010: Stiftung Deutsche Schlaganfall-Hilfe
  • 2009: Brustkrebs Deutschland e.V.
  • 2008: Stiftung Kindergesundheit
  • 2007: Deutsche Parkinsonvereinigung e.V.
  • 2006: Felix Burda Stiftung
  • 2005: Aktion Knochenmarkspende Bayern e.V.